Coya Therapeutics (COYA) Fundamental Analysis: Revenue, Earnings & Valuation

0.84 / 10

Underperform

Fundamental analysis rates COYA as Underperform, with a 0.8/10 score. Cash‑up and revenue‑to‑market‑value are modest positives, but profit‑to‑market‑value and net‑income‑to‑revenue are weak. Overall, the company shows concerning financial health.

Analysis Checks(2/10)

Revenue-MV

Value-1.61

Score2/3

Weight0.97%

1M Return-0.38%

Net cash flow from operating activities / Operating revenue (%)

Value-135.16

Score0/3

Weight18.35%

1M Return-9.58%

Profit-MV

Value0.66

Score1/3

Weight6.51%

1M Return-2.85%

Net income-Revenue

Value-0.04

Score1/3

Weight5.83%

1M Return-2.58%

Net profit margin (%)

Value-267.14

Score0/3

Weight17.96%

1M Return-9.31%

Cash-UP

Value-0.15

Score3/3

Weight-6.84%

1M Return2.45%

Net cash flow from operating activities / Total liabilities (%)

Value-1.55

Score0/3

Weight13.14%

1M Return-6.78%

EBIT / Total operating revenue (%)

Value-1049.47

Score0/3

Weight17.58%

1M Return-9.03%

Asset-MV

Value-0.55

Score0/3

Weight8.54%

1M Return-3.70%

Net profit / Total operating revenue (%)

Value-267.14

Score0/3

Weight17.96%

1M Return-9.31%

Is COYA fundamentally strong?

COYA scores 0.84/10 on fundamentals and holds a Premium valuation at present. Backed by its -51.39% ROE, -267.14% net margin, -4.58 P/E ratio, 2.26 P/B ratio, and -29.59% earnings growth, these metrics solidify its Underperform investment rating.